Zhejiang Genfleet Therapeutics Co., Ltd. clinical trials
A subsidiary of Genfleet Therapeutics (Shanghai) Inc.
The registry lists 4 studies whose lead sponsor is Zhejiang Genfleet Therapeutics Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Mar 1, 2024.
- 4studies on the registry
- 0open to participants now
What it is testing
The drugs Zhejiang Genfleet Therapeutics Co., Ltd.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 4 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed250%
- Stopped early250%
Over the years
- 19
- 20
- 21
- 322
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Zhejiang Genfleet Therapeutics Co., Ltd.4 studies
Something wrong with this grouping? Tell us on the Genfleet Therapeutics (Shanghai) Inc. page.
Studies
Recruiting first, then most recently updated. Showing 4 of 4. All Genfleet Therapeutics (Shanghai) Inc. studies →
- A Study of GFH018 in Patients With Advanced Solid TumorsCompletedNCT05051241Phase 1
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.
- A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)WithdrawnNCT05618691Phase 2
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.
- A Phase I Study of GFH312 in Healthy Chinese SubjectsCompletedNCT05991362Phase 1
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.
- A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid TumorsWithdrawnNCT05165849Phase 1/2
Sponsor listed in the registry: Zhejiang Genfleet Therapeutics Co., Ltd.